Anex Vivopotency Assay to Assess Active Drug Levels of a GLP-1 Agonistic Peptide During Preclinical Safety Studies

Bioanalysis - United Kingdom
doi 10.4155/bio.15.189
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Science Ltd

Related search

Cardiovascular Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2014English

GLP-1 Influences Food and Drug Reward

Current Opinion in Behavioral Sciences
PsychiatryMental HealthBehavioral NeuroscienceCognitive Neuroscience
2016English

Glucagon-Like Peptide-1 Receptor (GLP1R; GLP-1R)

Science-Business eXchange
2009English

Pdb12 - Cardiovascular Safety of Empagliflozin Versus Glucagon-Like Peptide-1 (Glp-1) Receptor Agonists: Systematic Literature Review and Indirect Comparisons

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The International Intravitreal Bevacizumab Safety Survey: Using the Internet to Assess Drug Safety Worldwide

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2006English

Proposing an Agonistic Analytical Framework to Assess Participatory Initiatives in Brazil

Revista do Serviço Público
2016English

Drug-Induced Physeal Abnormalities in Preclinical Toxicity Studies

Toxicologic Pathology
Forensic MedicineToxicologyPathologyCell BiologyMolecular Biology
2017English

Validation of the Filovirus Plaque Assay for Use in Preclinical Studies

Viruses
VirologyInfectious Diseases
2016English

Characterization of Dysferlin Deficient SJL/J Mice to Assess Preclinical Drug Efficacy: Fasudil Exacerbates Muscle Disease Phenotype

PLoS ONE
Multidisciplinary
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy